CalcMyPeptide
Healing & RecoveryAlso known as: Body Protection Compound-157, Pentadecapeptide

BPC-157

BPC-157 is a synthetically derived, 15-amino acid partial sequence of a natural body protection compound discovered in human gastric juice. Clinically revered in regenerative medicine, this pentadecapeptide exhibits profound systemic healing properties by radically accelerating the repair of muscle, tendon, ligament, and mucosal tissue. Often referred to as the "Wolverine Peptide," it is heavily utilized in sports optimization and physical therapy for both catastrophic injuries and chronic tendinopathies.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Strong preclinical6 peer-reviewed citations

Quick Stats

Half-Life4-6 hours
Dose Range200-800 mcg/day
Frequency1-2× daily
Vial Sizes5 mg
Bioavailability~100% (subcutaneous)
Year Developed1992

Scientific Data

Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
CAS Number
PubChem ID

Patient Suitability

Best For

  • Tendon and ligament injuries
    Sprains, strains, tears, tendinitis - accelerates collagen synthesis
  • Gut healing
    IBS, leaky gut, ulcers, inflammatory bowel conditions
  • Muscle injuries
    Strains, post-workout recovery, chronic muscle issues
  • Joint problems
    Arthritis support, joint pain, cartilage issues

Avoid If

  • Pregnancy
  • Breastfeeding
  • Active cancer
  • History of cancer

! Use With Caution If

  • Chronic medical conditions
  • Prescription medication use
  • History of allergic reactions

Mechanism of Action

BPC-157 (Body Protection Compound-157) is a pentadecapeptide consisting of 15 amino acids derived from human gastric juice. Its primary mechanism involves upregulation of growth factor expression, including VEGF (Vascular Endothelial Growth Factor) and FGF (Fibroblast Growth Factor), which promote angiogenesis — the formation of new blood vessels. This enhanced blood supply accelerates tissue repair in tendons, ligaments, muscles, and the gastrointestinal tract.

BPC-157 also modulates the nitric oxide (NO) system, which plays a critical role in blood vessel formation and wound healing. Studies demonstrate its ability to counteract the damage caused by NSAIDs on the gastric mucosa, and to promote tendon-to-bone healing in animal models. It has additionally shown neuroprotective effects and the ability to counteract dopaminergic system disturbances.

Source: PMID: 29936067, PMID: 30915550

Background & History

BPC-157 (Body Protection Compound-157) was first isolated from human gastric juice by Croatian pharmacologist Predrag Sikiric in the 1990s. The 15-amino-acid pentadecapeptide was engineered to be stable in gastric acid — unlike most peptides — enabling both oral and injectable administration. Decades of animal model research at the University of Zagreb have documented its systemic healing effects across virtually every tissue type.

Research Use Cases

  • Tendon and ligament repair after acute injury or overuse
  • Gastrointestinal healing: IBD, leaky gut, NSAID-induced ulcers
  • Accelerating bone fracture healing
  • Nerve repair and neuroprotection after spinal or peripheral injury
  • Reducing post-surgical adhesions and inflammation

Dosing Protocols

🌱

Starting Dose

Dose
250 mcg
Frequency
Once daily
Duration
1-2 weeks
Note: Start here to assess tolerance. Can split into AM/PM if preferred.

Standard Protocol

Dose
250-500 mcg
Frequency
Twice daily
Duration
4-6 weeks
Note: Most common protocol. Split doses morning and evening for best results.

Advanced Protocol

Dose
500 mcg
Frequency
Twice daily
Duration
6-8 weeks
Note: For experienced users or severe injuries. Higher doses not shown to improve outcomes significantly.

When to Increase:

  • Current dose is well-tolerated for 2+ weeks
  • Desired effects not yet noticeable
  • Healthcare provider recommends dose increase

When to Decrease:

  • Side effects become bothersome or persistent
  • Desired effects achieved at lower dose
  • Healthcare provider recommends reduction

Body-Weight Dosing Reference

Estimated doses extrapolated from the published research range of 200800 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.

WeightLowTargetHigh
120 lb(54 kg)154 mcg386 mcg617 mcg
140 lb(63 kg)180 mcg450 mcg720 mcg
160 lb(73 kg)209 mcg521 mcg834 mcg
180 lb(82 kg)234 mcg586 mcg937 mcg
200 lb(91 kg)260 mcg650 mcg1040 mcg
220 lb(100 kg)286 mcg714 mcg1143 mcg
250 lb(113 kg)323 mcg807 mcg1291 mcg

💉 For exact syringe units based on your vial concentration, use the BPC-157 Reconstitution Calculator →

Administration & Storage

Preparation

Route
Subcutaneous injection (into the fatty tissue just under the skin)
Best Injection Sites
Lower abdomen (2 inches from navel), Outer thigh (middle third), Back of upper arm
Required Supplies
  • Bacteriostatic water (BAC water)
  • Insulin syringes (29-31 gauge)
  • Alcohol swabs
  • Sharps container

Storage Guidelines

Before Reconstitution
Store in refrigerator at 36-46°F (2-8°C). Keep in original packaging to protect from light. Do not freeze.
After Reconstitution
Store reconstituted solution in refrigerator at 36-46°F (2-8°C). Use within 30 days. Do not freeze reconstituted solution.
! Signs of Degradation
Solution appears cloudy or discolored • Visible particles or precipitates in solution • Solution has changed color • Exposed to temperatures above 77°F (25°C) for extended periods

Reconstitution Example

Vial
5 mg
Water
2 mL
Concentration
2.5 mg/mL
Per Unit (100u syringe)
25 mcg
Dose of 200 mcg = 8 units on a 100-unit insulin syringe

Safety & Considerations

BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses. Maintain sterile injection technique and consult a healthcare provider.

Regulatory & Legal Status

FDA Status (US)
Research Only

FDA Category 2 (higher-risk compound) — not approved for human use

WADA Status (2026)
Prohibited (S0)

Competitive athletes subject to anti-doping controls should not use BPC-157.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Interactions & Contraindications

Avoid concurrent use with active cancer treatment — angiogenic properties may theoretically promote tumor vascularization. NSAIDs blunt the prostaglandin pathway BPC-157 modulates; minimize concurrent use. No established drug-drug interactions with common medications at research doses.

Synergies & Common Stacks

The most studied peptide stack for recovery: BPC-157 drives localized VEGF/FGF healing while TB-500 provides systemic actin-mediated repair. Together they cover both local and systemic dimensions.

GHK-Cu amplifies collagen synthesis alongside BPC-157's angiogenic effects, enhancing tissue remodeling especially in skin and connective tissue repairs.

MGF activates satellite cells for muscle repair while BPC-157 handles the vascular and structural repair phase, making this stack useful for muscle injuries.

BPC-157 vs. TB-500

AttributeBPC-157TB-500
OriginGastric juice pentadecapeptide (human)Thymosin β4 (Tβ4) synthetic fragment
MechanismVEGF/FGF angiogenesis + NO pathwayActin polymerization + cell migration
Best ForLocalized tissue healing + gut repairSystemic whole-body healing
Injection SiteNear injury site preferredAny site — systemic distribution
Dose Frequency250–500 mcg 1–2× daily2–5 mg 2× weekly (loading phase)
WADA StatusProhibited (S0)Prohibited (S0)
Evidence LevelPreclinical (animal models)Preclinical (limited human data)

Verdict: BPC-157 is best for localized injury healing and GI repair; TB-500 distributes systemically and addresses whole-body repair via the actin signaling axis. Most research protocols combine both for comprehensive recovery coverage.

What to Expect

Weeks 1-2

You Might Notice:
  • Reduced inflammation
  • Less pain at injury site
  • Improved gut comfort
Next Steps:
  • Continue protocol
  • Maintain consistent timing

Weeks 3-4

You Might Notice:
  • Noticeable improvement in injury healing
  • Increased mobility
  • Significant gut symptom relief
Next Steps:
  • Assess if dose adjustment needed
  • Continue if seeing progress

Weeks 5-6+

You Might Notice:
  • Substantial or complete healing
  • Return to normal activity
  • Lasting improvements
Next Steps:
  • Consider stopping if healed
  • Take 2-4 week break

Dosing Quick Reference

BPC-157— Dosing Guide
Dose Range
200-800 mcg/day
Half-Life
4 hours
Frequency
1-2× daily
Route
Subcutaneous
5 mg vial
💧 2 mL BAC water📐 2.5 mg/mL concentration💉 25 mcg/unit (100u syringe)
Healing & Recoverycalcmypeptide.com

Frequently Asked Questions

What is the standard BPC-157 dose?
The most common dose is 250-500 mcg injected subcutaneously once or twice daily. For a 5 mg vial reconstituted with 2 mL of bacteriostatic water, each 10 units on a 100-unit insulin syringe delivers 250 mcg.
How long should I run a BPC-157 cycle?
Typical protocols run 4-6 weeks for injury recovery. Some protocols extend to 8-12 weeks for chronic conditions. There is no established need for "cycling off" based on current research.
Should I inject BPC-157 near the injury site?
Injecting subcutaneously as close to the injury site as practical is the most common approach. However, systemic (abdominal) injection also shows efficacy in research, as BPC-157 has demonstrated whole-body healing properties.
Can I stack BPC-157 with TB-500?
BPC-157 and TB-500 are commonly stacked for synergistic recovery. BPC-157 promotes localized healing via VEGF/FGF, while TB-500 supports systemic healing through actin regulation. Use our Blend/Stack Calculator to calculate combined doses.

References

  1. Sikiric et al. "BPC 157 and its role in healing".” Journal of Physiology-Paris (2018). PMID: 29898669
  2. Seiwerth et al. "Gastric pentadecapeptide BPC 157 and wound healing".” Expert Opin Investig Drugs (2014). PMID: 24799263
  3. Chang et al. "Effect of BPC 157 on tendon healing".” J Appl Physiol (2011). PMID: 21030672

📚 Related Articles

Recommended Source10% OFF

Get BPC-157 from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.

Affiliate link · Full review